Subscribe To Our Free Newsletter |
Gland Pharma soars 7% on USFDA approval for breast cancer drug
The Eribulin Mesylate injection is indicated for treating patients diagnosed with metastatic breast cancer (mBC) who have undergone at least two rounds of chemotherapy for managing metastatic disease